EVEROLIMUS vs HYFTOR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Possible drug interaction. EVEROLIMUS and HYFTOR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	HYFTOR
Rating	70/100	New
Pharmacy pays	~$229.16 /30	~$48.61 /30
Type	RX	RX
Active ingredient	EVEROLIMUS	SIROLIMUS
Manufacturer	Biocon Pharma	Nobelpharma
Dosage forms	Tablet	Topical
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

everolimus hyftor

Rating

70/100

New

Pharmacy pays

~$229.16 /30

~$48.61 /30

Type

Active ingredient

EVEROLIMUS

SIROLIMUS

Manufacturer

Biocon Pharma

Nobelpharma

Dosage forms

Tablet

Topical

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Frequently asked questions

Which is cheaper, Everolimus or Hyftor?

Hyftor costs pharmacies less to acquire — about $48.61 vs $229.16 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Everolimus and Hyftor?

Everolimus contains Everolimus, while Hyftor contains Sirolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.